The company believes therapeutic neurogenesis can revolutionize the treatment of several currently incurable neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease. NeuroNova uses its integrated platform of drug discovery technologies, the Neurogenesis Qualifier, to identify novel drug targets and existing drugs that can stimulate the formation of new neurons in the brain.